EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Toward an all-in-one recombinant adeno-associated virus vector for functionally ablating the prion gene using CRISPR-Cas technology

Claire Verkuyl, Ari Belotserkovsky, Thomas Zerbes, Declan Williams, Medha R Krishnan, Sabrina Zhu, Sophie Grunnesjӧ, Shehab Eid, Cunjie Zhang, Wenda Zhao, Leo Xu, Eleanore Lin iD und 5 weitere

PLOS One · 2025

DOI: 10.1371/journal.pone.0336578 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Claire Verkuyl und 16 weiteren Autor:innen. Beteiligte Einrichtung: Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Dependovirus, CRISPR-Cas Systems, Genetic Vectors. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institutes for Health Research, Canadian Foundation for Innovation, Krembil Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Any strategy that can selectively and persistently lower the brain levels of the cellular prion protein (PrP C ) is expected to extend survival in prion diseases. Recent advances in the virus-mediated delivery of gene therapies prompted us to explore if a recombinant adeno-associated virus (rAAV) vector delivering a CRISPR-Cas-based gene editor can be devised that induces a functional knockout of the prion gene. Whereas the eventual objective is to assess the therapeutic potency of an optimized vector in prion-infected mice, in this proof-of-concept study, we evaluated tools and methods that are suited to achieve this goal. The result of these efforts is a first-generation all-in-one rAAV vector that codes for a prion gene-specific guide RNA and a small Cas9 endonuclease, whose expression is controlled by a truncated neural cell adhesion molecule 1 (NCAM1) promoter that is active in PrP C expressing cells. We also constructed a second rAAV vector coding for a prion gene-specific ‘traffic light reporter’ (TLR). The TLR can be used to monitor prion gene-editing efficacy by coding for red and green fluorescent proteins separated by a segment of the prion gene that is targeted by the gene editor. For the purification of AAVs, we adopted a robust and scalable rAAV vector assembly pipeline and undertook proof-of-concept prion gene editing experiments in human cells and mice, which to date yielded prion gene editing rates of approximately 20% and 5%, respectively. Finally, we compared brain distributions of rAAV vectors following intrathalamic versus retro-orbital injection, and selected the 9P31 capsid for future studies based on a 7.5-fold higher heterologous gene expression level as compared to the PHP.eB capsid.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DependovirusCRISPR-Cas SystemsGenetic VectorsAnimalsMiceHumansGene EditingGenetic TherapyPrion DiseasesRNA, Guide, CRISPR-Cas SystemsHEK293 Cells

Substanzen

RNA, Guide, CRISPR-Cas Systems

Autor:innen und Institutionen

  • Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.
  • Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, Ontario, Canada.
  • Megadalton Solutions, Inc., and Department of Chemistry, Indiana University, Bloomington, Indiana, United States of America.
  • German Centre for Cardiovascular Research (DZHK), Heidelberg, Germany.
  • Department of Internal Medicine III Cardiology, University of Heidelberg, Heidelberg, Germany.

ORCID-Profile: Eleanore Lin, Gerold Schmitt-Ulms

Förderung

  • Canadian Institutes for Health Research
  • Canadian Foundation for Innovation
  • Krembil Foundation
  • Canada Graduate Scholarship

Zitieren

APA

Verkuyl, C., Belotserkovsky, A., Zerbes, T., Williams, D., Krishnan, M. R., Zhu, S., Grunnesjӧ, S., Eid, S., Zhang, C., Zhao, W., Xu, L., Lin, E., O'Shea, T., Draper, B., Jungman, A., Most, P., & Schmitt-Ulms, G. (2025). Toward an all-in-one recombinant adeno-associated virus vector for functionally ablating the prion gene using CRISPR-Cas technology. PLOS One. https://doi.org/10.1371/journal.pone.0336578

Vancouver

Verkuyl C, Belotserkovsky A, Zerbes T, Williams D, Krishnan MR, Zhu S, et al. Toward an all-in-one recombinant adeno-associated virus vector for functionally ablating the prion gene using CRISPR-Cas technology. PLOS One. 2025. doi:10.1371/journal.pone.0336578

BibTeX
@article{Verkuyl2025,
  author = {Verkuyl, Claire and Belotserkovsky, Ari and Zerbes, Thomas and Williams, Declan and Krishnan, Medha R and Zhu, Sabrina and Grunnesjӧ, Sophie and Eid, Shehab and Zhang, Cunjie and Zhao, Wenda and Xu, Leo and Lin, Eleanore and O'Shea, Teaghan and Draper, Benjamin and Jungman, Andreas and Most, Patrick and Schmitt-Ulms, Gerold},
  title = {Toward an all-in-one recombinant adeno-associated virus vector for functionally ablating the prion gene using CRISPR-Cas technology},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0336578}
}
Kostenlos starten →